Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España

Actualizado junio 2024

Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Para iniciar la búsqueda, teclee el texto en la barra a continuación.

UNK3093116TPX-0005-01A Study of Repotrectinib (TPX-0005)
in Patients With Advance Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Phase I / IIPhase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.RECLUTANDOOral repotrectinib (TPX-0005)8 SitesTurning Point Therapeutics, Inc.
UNK4985604DAY101-102A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations.
Thyroid Cancer, Papillary
Phase I / IIThis is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.RECLUTANDOTovorafenib
H. Clinic Barcelona
H. U. Vall d'Hebron
H. U. Ramón y Cajal
Day One Biopharmaceuticals, Inc.
CTIS: 2022-500397-34-00
26280673475-158A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Phase IIThyroid Carcinoma
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
RECLUTANDOPembrolizumabH.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
H. V. de la Victoria (Málaga)
Merck Sharp & Dohme Corp
22023-504898-206235216GETNE T2318 A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.Phase IISETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC).

The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.
Not yet RecruitingSacituzumab govitecan11 SitesGrupo Espanol de Tumores Neuroendocrinos
2020-001847-164589845BO41932Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialPhase IITreatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.RECLUTANDOPralsetinib
H. Vall d´Hebron (Barcelona)
F. Jimenez Diaz (Madrid)
H. 12 de Octubre (Madrid)
H.La Paz (Madrid)
H. la Fe (Valencia)
Hoffmann-La Roche
UNK3906331J2G-OX-Y001Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationExpanded AccessMedullary Thyroid Cancer
Papillary Thyroid Cancer
Other Solid Tumors With Evidence of Activating RET Alteration
DISPONIBLESelpercatinibH.U. Vall d´Hebron (Barcelona)
Start_Sanchinarro (Madrid)
Loxo Oncology, Inc.
UNK6292988MYELOPredective Factors for Tumor Aggressiveness in Medullary Thyroid CancerRetrospectiveMedullary Thyroid CancerNot yet RecruitingTotal ThyroidectomyC.H. de Vigo
H. Clinic (BCN)
H.U. Cordoba
H. Regional Málaga
Aristotle University Of Thessaloniki

Puede seleccionar el número de filas a representar entre: 4, 8 o 10